Transaction · 0001193125-26-357225

Readnour Robin Shane

Readnour Robin Shane, DIR, reported an open-market or private sale at AN2 Therapeutics, Inc. involving 18706.000000 shares for an estimated $112389.39. Reported holdings after the transaction were 633867.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SDIR
ANTXAN2 Therapeutics, Inc.
Trade date
Aug 17, 2026
Filing date
Aug 19, 2026
View on SEC Insider profile
Estimated value-$112kShares × reported price
Shares traded18.7k$6.01 per share
Holdings after633kIndirect · See footnotes
% of reported position traded2.87%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 652,573 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ANTX price since this filing

Daily closing prices, with the filing date and available return windows
ANTX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -21.5%1w ago -0.8%1d ago +0.5%
Returns since7d -7.2%30d -15.3%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-357225
Common Stock
Transaction date
Aug 17, 2026
Filed Aug 19, 2026, 09:58 PM · 2d delay
Shares
18,706 sh
$6.01 per share
Estimated value
-$112k
Computed from shares × price
Holdings after
633,867 sh
Indirect · See footnotes

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Repeat Seller 10b5-1 Detected
Filing-only score

-6 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP ("MGC 2018 LP") on April 23, 2026.

  2. F2

    The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP ("MGC 2018 QP") on April 23, 2026.

  3. F3

    Represents the weighted average sale price for multiple transactions ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer…

  4. F4

    MGC Venture Partners 2018 GP, LLC ("MGC 2018 GP") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP…

  5. F5

    Shares held directly by MGC 2018 LP.

  6. F6

    Shares held directly by MGC 2018 QP.

Original filing · 0001193125-26-357225
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ANTX